Things have been looking better since January.
The Boston firm unveils positive results from its Phase 3 study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
If they are breached, that will trigger more aggressive selling.
This is pretty typical Fed Day action, when traders do some quick trades while they wait.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.